Cargando…
Renal outcomes with sodium-glucose cotransporters 2 inhibitors
Diabetic nephropathy (DN) is one of the most serious complications of diabetes. Therefore, delaying and preventing the progression of DN becomes an important goal in the clinical treatment of type 2 diabetes mellitus. Recent studies confirm that sodium-glucose cotransporters 2 inhibitors (SGLT2is) h...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752889/ https://www.ncbi.nlm.nih.gov/pubmed/36531469 http://dx.doi.org/10.3389/fendo.2022.1063341 |
_version_ | 1784850840059641856 |
---|---|
author | Sun, Xiaoya Wang, Guohong |
author_facet | Sun, Xiaoya Wang, Guohong |
author_sort | Sun, Xiaoya |
collection | PubMed |
description | Diabetic nephropathy (DN) is one of the most serious complications of diabetes. Therefore, delaying and preventing the progression of DN becomes an important goal in the clinical treatment of type 2 diabetes mellitus. Recent studies confirm that sodium-glucose cotransporters 2 inhibitors (SGLT2is) have been regarded as effective glucose-lowering drugs with renal protective effect. In this review, we summarize in detail the present knowledge of the effects of SGLT2is on renal outcomes by analyzing the experimental data in preclinical study, the effects of SGLT2is on estimated glomerular flitration rates (eGFRs) and urinary albumin-creatinine ratios (UACRs) from clinical trials and observational studies, and renal events (such as renal death or renal failure requiring renal replacement therapy) in some large prospective cardiovaslucar outcomes trials. The underlying mechanisms for renoprotective activity of SGLT2is have been demondtrated in multiple diabetic and nondiabetic animal models including kidney-specific effects and secondary kidney effects related to amelioration in blood glucose and blood pressure. In conclusion, these promising results show that SGLT2is act beneficially in terms of the kidney for diabetic patients. |
format | Online Article Text |
id | pubmed-9752889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97528892022-12-16 Renal outcomes with sodium-glucose cotransporters 2 inhibitors Sun, Xiaoya Wang, Guohong Front Endocrinol (Lausanne) Endocrinology Diabetic nephropathy (DN) is one of the most serious complications of diabetes. Therefore, delaying and preventing the progression of DN becomes an important goal in the clinical treatment of type 2 diabetes mellitus. Recent studies confirm that sodium-glucose cotransporters 2 inhibitors (SGLT2is) have been regarded as effective glucose-lowering drugs with renal protective effect. In this review, we summarize in detail the present knowledge of the effects of SGLT2is on renal outcomes by analyzing the experimental data in preclinical study, the effects of SGLT2is on estimated glomerular flitration rates (eGFRs) and urinary albumin-creatinine ratios (UACRs) from clinical trials and observational studies, and renal events (such as renal death or renal failure requiring renal replacement therapy) in some large prospective cardiovaslucar outcomes trials. The underlying mechanisms for renoprotective activity of SGLT2is have been demondtrated in multiple diabetic and nondiabetic animal models including kidney-specific effects and secondary kidney effects related to amelioration in blood glucose and blood pressure. In conclusion, these promising results show that SGLT2is act beneficially in terms of the kidney for diabetic patients. Frontiers Media S.A. 2022-12-01 /pmc/articles/PMC9752889/ /pubmed/36531469 http://dx.doi.org/10.3389/fendo.2022.1063341 Text en Copyright © 2022 Sun and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Sun, Xiaoya Wang, Guohong Renal outcomes with sodium-glucose cotransporters 2 inhibitors |
title | Renal outcomes with sodium-glucose cotransporters 2 inhibitors |
title_full | Renal outcomes with sodium-glucose cotransporters 2 inhibitors |
title_fullStr | Renal outcomes with sodium-glucose cotransporters 2 inhibitors |
title_full_unstemmed | Renal outcomes with sodium-glucose cotransporters 2 inhibitors |
title_short | Renal outcomes with sodium-glucose cotransporters 2 inhibitors |
title_sort | renal outcomes with sodium-glucose cotransporters 2 inhibitors |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752889/ https://www.ncbi.nlm.nih.gov/pubmed/36531469 http://dx.doi.org/10.3389/fendo.2022.1063341 |
work_keys_str_mv | AT sunxiaoya renaloutcomeswithsodiumglucosecotransporters2inhibitors AT wangguohong renaloutcomeswithsodiumglucosecotransporters2inhibitors |